Targets › BRACHYURY
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: the race on BRACHYURY, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1 | CEA, BRACHYURY, MUC1, KLK3, TBXT | Phase 2 | Adenocarcinoma; Metastatic Colorectal Cancer | Oct 2027 |
Adenocarcinoma (1) Metastatic Colorectal Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.